To answer the question as to the prevalence of @entity1274 ( @entity1274 ) among neonates receiving ECMO, a retrospective chart review was conducted on 198 @entity1 having surgery between November 1987 and January 1995. One hundred fifty-seven (79.7%) survived. One hundred thirty @entity1 met our criteria of having a pre-discharge auditory brainstem evoked response (ABR) test and at least one follow-up behavioral audiologic examination. Strict criteria were set for normal hearing on both the ABR and follow-up examinations. Only follow-up results are reported. At the time of the most recent follow-up examination, two @entity1 could not be adequately studied, 106 exhibited normal hearing, 21 (16%) exhibited either unilateral or bilateral conductive @entity393 and three (2.3%) exhibited unilateral or bilateral @entity1274 . Only one @entity1 is using amplification. With the largest sample size to date, we found a lower prevalence of @entity1274 after ECMO than has been previously noted in the literature. Although the prevalence of @entity393 is low, the post-ECMO group of @entity1 must be considered at risk for @entity393 . The prevalence of @entity393 cannot be based solely on a pre-discharge ABR, i.e. ongoing follow-up testing is necessary.

XXXX associated with neonatal ECMO: a clinical investigation.

@entity1 :: ('9606', 'Species') :: ['children', 'infants', 'child'] @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss'] @entity1274 :: ('MESH:D006319', 'Disease') :: ['sensori-neural hearing loss', 'SNHL']
@entity393 :: (MESH:D034381,Disease) :: ['Hearing loss']
